Cyclophosphamide hydrate
Code | Size | Price |
---|
TAR-T0707-1mL | 1 mL * 10 mM (in DMSO) | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0707-50mg | 50mg | £97.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0707-100mg | 100mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0707-200mg | 200mg | £117.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0707-500mg | 500mg | £140.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0707-1g | 1g | £177.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
CAS:
6055-19-2
Formula:
C7H17Cl2N2O3P
Molecular Weight:
279.1
Pathway:
Immunology/Inflammation; DNA Damage/DNA Repair
Purity:
0.98
SMILES:
O.ClCCN(CCCl)P1(=O)NCCCO1
Target:
DNA Alkylator/Crosslinker; DNA; MRP
References
1. Lutsiak ME, et al. Blood, 2005, 105(7), 2862-2868.
2. Chang TK, et al. Cancer Res, 1997, 57(10), 1946-1954.
3. Anderson D, et al. Mutat Res, 1995, 330(1-2), 115-181.
4. Machiels JP, et al. Cancer Res, 2001, 61(9), 3689-3697.
5. Lv M, Chen M, Zhang R, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy[J]. Cell Research. 2020, 30(11): 966-979.